The benzothiazepine diltiazem blocks ionic current through L-type Ca 2ϩ channels, as do the dihydropyridines (DHPs) and phenylalkylamines (PAs), but it has unique properties that distinguish it from these other drug classes. Wild-type L-type channels containing ␣ 1CII subunits, wild-type P/Q-type channels containing ␣ 1A subunits, and mutants of both channel types were transiently expressed in tsA-201 cells with ␤ 1B and ␣ 2 ␦ subunits. Whole-cell, voltage-clamp recordings showed that diltiazem blocks L-type Ca 2ϩ channels approximately 5-fold more potently than it does P/Q-type channels. Diltiazem blocked a mutant P/Q-type channel containing nine amino acid changes that made it highly sensitive to DHPs, with the same potency as L-type channels. Thus, amino acids specific to the L-type channel that confer DHP sensitivity in an ␣ 1A background also increase sensitivity to diltiazem. Analysis of single amino acid mutations in domains IIIS6 and IVS6 of ␣ 1CII subunits confirmed the role of these L-type-specific amino acid residues in diltiazem block, and also indicated that Y1152 of ␣ 1CII , an amino acid critical to both DHP and PA block, does not play a role in diltiazem block. Furthermore, T1039 and Y1043 in domain IIIS5, which are both critical for DHP block, are not involved in block by diltiazem. Conversely, three amino acid residues (I1150, M1160, and I1460) contribute to diltiazem block but have not been shown to affect DHP or PA block. Thus, binding of diltiazem to L-type Ca 2ϩ channels requires residues that overlap those that are critical for DHP and PA block as well as residues unique to diltiazem.
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L-type voltage-gated Ca
2ϩ channels play a critical role in the initiation of muscle contraction in the cardiovascular system and also contribute to the timing of the cardiac action potential (Bers and Perez-Reyes, 1999) . Therefore, drugs that inhibit Ca 2ϩ flux through L-type Ca 2ϩ channels are used to treat hypertension, angina pectoris, and some cardiac arrhythmias. Three major classes of Ca 2ϩ channel blockers are currently in clinical use: dihydropyridines (DHP), phenylalkylamines (PA), and benzothiazepines (BZP). Ca 2ϩ channels are composed of a large, pore-forming ␣ 1 subunit consisting of four homologous domains (I-IV), each containing six transmembrane segments (S1-S6), in a complex with auxiliary ␤, ␥, and ␣ 2 ␦ subunits Tanabe et al., 1987; Catterall, 1995) . L-type Ca 2ϩ channels in the heart and vascular smooth muscle contain ␣ 1c subunits, which are highly sensitive to Ca 2ϩ channel blocking drugs, whereas the drug-insensitive N-type and P/Q-type Ca 2ϩ channels contain ␣ 1B and ␣ 1A subunits, respectively (reviewed in Hofmann et al., 1999) .
Drugs from all three of these classes bind to L-type Ca 2ϩ channels, and their binding sites are closely linked but not identical (Gould et al., 1983) . Biochemical experiments utilizing photoreactive derivatives of DHPs and PAs indicated interaction of DHPs with domains IIIS6 and IVS6 (Nakayama et al., 1991; Striessnig et al., 1991) , and PAs with domain IVS6 of the ␣ 1 subunit (Striessnig et al., 1990) . Subsequent experiments using site-directed mutagenesis and electrophysiological recordings of recombinant channels expressed in various cell types have led to a detailed picture of the amino acid residues required for modulation of L-type Ca 2ϩ channels by DHPs and PAs (Hockerman et al., 1997b; Mitterdorfer et al., 1998; Hofmann et al., 1999) .
The site of action for BZPs has been less extensively characterized. Diltiazem, a clinically relevant member of the BZP class of drugs, has several unique properties that suggest that its binding site is distinct from that of DHPs or PAs. Diltiazem stimulates the binding of DHPs but inhibits the binding of PAs to L-type Ca 2ϩ channels (DePover et al., 1982; Ferry and Glossmann, 1982) suggesting that there are elements of the DHP binding site that are distinct from the BZP binding site. In addition, block of L-type Ca 2ϩ channels by diltiazem is frequency-dependent, similar to but less pronounced than the frequency-dependent block by PAs (Lee and Tsien, 1983) . This suggests that both diltiazem and PAs bind preferentially to the open and/or inactivated states of the channel, and may therefore share some common binding determinants within the channel. Finally, diltiazem shows lower selectivity for L-type versus non-L-type Ca 2ϩ channels than DHPs or PAs (Diochot et al., 1995; Ishibashi et al., 1995) . This suggests that many of the binding determinants for diltiazem are identical across Ca 2ϩ channel types, or that differences at these positions are conservative enough to allow diltiazem binding.
Biochemical experiments using a photoreactive BZP reported derivatization of transmembrane segments IIIS6 and IVS6 of L-type Ca 2ϩ channels (Kraus et al., 1996) . Subsequent studies using chimeric Ca 2ϩ channels with IIIS6 and IVS6 segments from ␣ 1C spliced into an ␣ 1A background found that many of the same amino acid residues critical for high affinity PA block (Hockerman et al., 1995 (Hockerman et al., , 1997a were also involved in diltiazem block . To date, no studies have systematically examined the role of each amino acid residue in the IIIS6 and IVS6 segments. Therefore, we have constructed single amino acid mutations to alanine along the entire IIIS6 and IVS6 segments of ␣ 1C and have analyzed each mutant for sensitivity to block by diltiazem. In addition, we have measured the sensitivity to diltiazem block of both the wild-type ␣ 1A (P/Qtype) channel and an ␣ 1A mutant (␣ 1A/DHPS ) that contains the DHP binding site. To assess the contribution to diltiazem block of amino acid residues in transmembrane domain IIIS5 known to be critical for DHP block He et al., 1997) , we have constructed a double amino-acid mutation in IIIS5 (␣ 1C/DHPI ) and analyzed it for sensitivity to both the DHP PN200 -110 and diltiazem. Our results reveal several amino acid residues that contribute to block by diltiazem but not by DHPs and/or PAs; conversely, several key amino acid residues contribute to block by DHPs and/or PAs but do not contribute to block by diltiazem.
Experimental Procedures
Construction of Mutants. Single amino acid mutations in domains IIIS6 and IVS6 of the ␣ 1C subunit (Snutch et al., 1991) were constructed using oligonucleotide-directed mutagenesis, as described previously (Kunkel, 1985) . The IIIS6 mutations were inserted into full-length subunit constructs in the expression vector Zem 229 (Dr. Eileen Mulvihill, University of Washington, Seattle, WA) using the 1.5-kilobase SpeI/DraIII fragment and the 272 bp DraIII/DraIII fragment in a three-way ligation. Construction of the ␣ 1A/DHPS mutant was described previously (Hockerman et al., 1997c) . The ␣ 1C/DHPI mutant contains two mutations in domain IIIS5 (T1039 to Y and Q1043 to M) and was constructed using the splice overlap extension method (Horton et al., 1989) . The mutant 600-bp DNA fragment was cut with SpeI and BglII and inserted into the full-length subunit construct in the expression vector Zem 229 using the 900-bp BglII// DraIII fragment and the 272-bp DraIII/DraIII fragment in a fourway ligation. All mutations were confirmed by cDNA sequencing.
Cell Culture. tsA201 cells, a subclone of the human embryonic kidney cell line 293 that expresses simian virus 40 T antigen (a gift of Dr. Robert Dubridge, Cell Genesis, Foster City, CA) were maintained in monolayer culture in Dulbecco's modified Eagle's medium/ Ham's F-12 medium (Life Technologies, Inc., Gaithersburg, MD), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), and incubated at 37°C in 10% CO 2 .
Expression. Wild-type and mutant ␣ 1C channel subunits (Snutch et al., 1991) were expressed with ␤ 1B (Pragnell et al., 1991) (Margolskee et al., 1993) or the transfection reagent GenePorter (Gene Therapy Systems, San Diego, CA). Transfectants were selected by labeling with anti-CD8 antibodies conjugated to polystyrene beads (Dynal, Oslo, Norway) or by fluorescence at 510 nm with excitation at 480 nm (enhanced green fluorescent protein transfected cells).
Electrophysiology. Ba 2ϩ currents through Ca 2ϩ channels were measured using the whole-cell, patch-clamp configuration. Pipettes were pulled from VWR micropipettes (VWR, West Chester, PA) and fire polished to produce an inner tip diameter of 4 to 6 m. Currents were recorded using an Axon Instruments Axopatch 200B amplifier and filtered at 1 or 2 kHz (six-pole Bessel filter, Ϫ3 dB). Voltage pulses were applied and data were acquired using pClamp6 software (Axon Instruments, Foster City, CA). Voltage-dependent currents have been corrected for leak using an online P/Ϫ4 subtraction paradigm. (ϩ)-cis-Diltiazem (RBI, Natick, MA) dissolved in bath saline was applied to cells under voltage clamp using a fast perfusion system with constant exchange of the bath solution. PN200-110 was added to the bath without background perfusion as a 3ϫ stock. The bath saline contained 150 mM Tris, 10 mM BaCl 2 , and 4 mM MgCl 2 . The intracellular solution contained 130 mM N-methyl-D-glucamine, 10 mM EGTA, 60 mM HEPES, 2 mM MgATP, 1 mM MgCl 2 . The pH of both solutions was adjusted to 7.3 with methanesulfonic acid. All experiments were done at room temperature (20-23°C).
Results

Block of Ca
2؉ Channels Containing Wild-Type ␣ 1C and ␣ 1A Subunits by (؉)-cis-Diltiazem. The ␣ 1C subunit (Snutch et al., 1991) was expressed in tsA201 cells along with the ␤ 1B (Pragnell et al., 1991) and ␣ 2 ␦ (Ellis et al., 1988) subunits. Ba 2ϩ currents through the resulting L-type channels were blocked by (ϩ)-cis-diltiazem with an IC 50 value of 33.3 Ϯ 4.6 M (Fig. 1A, F ). For L-type channels, a holding potential of Ϫ60 mV with a 100-ms test pulse to ϩ10 mV at a frequency of 0.05 Hz was used. Under these conditions, block developed rapidly, and reached equilibrium within 200 s (Fig. 1B) . Little (Ͻ10%) frequency-dependent block accumulated using this low stimulation frequency. These conditions were used for the assay of diltiazem sensitivity of all the ␣ 1C mutants.
In addition to the L-type Ca 2ϩ channel containing wildtype ␣ 1C , we also measured the concentration dependence of diltiazem block of the P/Q-type Ca 2ϩ channel containing wild-type ␣ 1A (Stea et al., 1994) . These channels have been reported to be blocked by 2-to 10-fold higher concentrations of diltiazem than those required to block L-type Ca 2ϩ channels (Diochot et al., 1995; Ishibashi et al., 1995) . We expressed the ␣ 1A subunit along with the ␤ 1B and ␣ 2 ␦ subunits in tsA201 cells and applied increasing concentrations of (ϩ)-cis-diltiazem to cells under voltage clamp using a holding potential of Ϫ80 mV and 100-ms test pulses to 0 mV at a frequency of 0.033 Hz. A more negative holding potential (Ϫ80 mV) was used for ␣ 1A because the fraction of inactivated channels at this holding potential is similar to that of ␣ 1C at Ϫ60 mV (Hockerman et al., 1997c) . The lower frequency of stimulation was used to prevent accumulation of inactivated channels. We found that the wild-type ␣ 1A channel was blocked by diltiazem under these conditions with an IC 50 value of 169 Ϯ 10 M, only five times the IC 50 value for wild-type ␣ 1C (Fig. 1C, F) .
Block of Mutant Ca 2؉ Channels Containing ␣ 1A/DHPS and ␣ 1C/DHPI by (؉)-cis-Diltiazem. We hypothesized that Molecular Determinants of Ca 2؉ Channel Block by Diltiazem the difference in sensitivity to diltiazem block between the wild-type ␣ 1C and ␣ 1A channels might be caused by changes in relatively few amino acid residues. As an initial experiment, we tested the diltiazem affinity of a mutant ␣ 1A channel in which nine amino acids from ␣ 1C had been substituted. These substitutions had been shown previously to confer nearly full sensitivity to DHPs (Hockerman et al., 1997c) . We expressed this mutant, ␣ 1A/DHPS , along with the ␤ 1B and ␣ 2 ␦ subunits in tsA201 cells and applied increasing concentrations of (ϩ)-cis-diltiazem to cells under voltage clamp using a holding potential of Ϫ120 mV and 100-ms test pulses to 0 mV at a frequency of 0.033 Hz. The strongly negative holding potential was necessary to compensate for the very negative voltage dependence of inactivation of the ␣ 1A/DHPS mutant (Hockerman et al., 1997c) . Diltiazem blocked Ba 2ϩ currents through ␣ 1A/DHPS with an IC 50 value of 35.5 Ϯ 13.6 M, a concentration virtually identical with that of wild-type ␣ 1C (Fig. 1, D and F) .
The nine L-type specific amino acids substituted in ␣ 1A/DHPS are in domains IIIS5, IIIS6, and IVS6 of ␣ 1A . Amino acid residues in transmembrane segments IIIS6 and IVS6 had been previously implicated in diltiazem block (Kraus et al., 1996) , so we focused on segment IIIS5. ␣ 1A/DHPS contains substitutions of two L-type-specific amino acid residues in IIIS5. We made a mutant L-type channel, ␣ 1C/DHPI , containing the converse changes by substituting T1039 with Y and Q1043 with M in domain IIIS5 of ␣ 1C . Mutation of these amino acids dramatically decreases DHP affinity for ␣ 1C He et al., 1997) . We expressed the ␣ 1C/DHPI mutant channel in tsA201 cells along with the ␤ 1B and ␣ 2 ␦ subunits and added increasing concentrations of (ϩ)-cis-diltiazem to cells under voltage clamp using a holding potential of Ϫ60 mV and test pulses to ϩ10 mV for 100 ms at 0.05 Hz. The wild-type ␣ 1C and ␣ 1C/DHPI could be compared at the same holding potential because their V 1/2 values for inactivation are not significantly different (data not shown). Although Ba 2ϩ currents through the resulting channels were not blocked by PN200-110 at 10 M (Fig. 1E) , the IC 50 value for diltiazem was not different from wild-type ␣ 1C (Fig. 1F) . Thus, T1039 and Q1043 are critical for DHP block but unnecessary for diltiazem block of ␣ 1C .
Effects of Single Amino Acid Alanine Substitution Mutants in Transmembrane Segment IIIS6 on Block by (؉)-cis-Diltiazem. Because photoaffinity labeling studies suggest that diltiazem interacts with both transmembrane domains IIIS6 and IVS6 (Kraus et al., 1996) , we screened a battery of single amino acid mutations to alanine spanning both the IIIS6 and IVS6 transmembrane domains of ␣ 1C for concentration-dependent block by diltiazem. At positions where the native amino acid is alanine, we substituted the corresponding amino acid in non-L-type channels (A1157P, A1467S). We also made more conservative changes at tyrosines 1152 and 1463, mutating them to phenylalanine. We expressed the ␣ 1C mutant channels in tsA201 cells along with the ␤ 1B and ␣ 2 ␦ subunits and added increasing concentrations of (ϩ)-cis-diltiazem to cells under voltage clamp using a holding potential of Ϫ60 mV and test pulses to ϩ10 mV for 100 ms at 0.05 Hz. Of the single amino acid mutations tested, only A1157P did not express current. The functional properties of the mutant channels that were expressed at low level have been described previously (Hockerman et al., 1997a) . Of the 21 single amino acid mutants in segment IIIS6 that we screened, eight had no significant change in diltiazem affinity, and six had Ͻ2-fold change in the IC 50 value for diltiazem (Fig. 2) . In contrast, mutants I1150A, I1153A, I1156A, and M1160A in the central portion of the segment had substantially reduced sensitivity to diltiazem block compared with wild-type ␣ 1C (I1150A, IC 50 ϭ 97.1 Ϯ 20.6 M; I1153A, IC 50 ϭ 93.1 Ϯ 24.4 M; I1156A, IC 50 ϭ 83.6 Ϯ 10.9 M; M1160A, IC 50 ϭ 107.9 Ϯ 7.7 M). In addition, mutation of two amino acid residues near the intracellular end of this transmembrane segment, F1164A and V1165A, also resulted in substantially decreased potency of diltiazem block of Ba 2ϩ current (F1164A, IC 50 ϭ 90.8 Ϯ 9.4 M; V1165A, IC 50 ϭ 131 Ϯ 40 M).
Effects of Block of Single-Amino-Acid Alanine Substitution Mutants in Transmembrane Segment IVS6 by (؉)-cis-Diltiazem. We also screened single-amino-acid mutations across transmembrane IVS6 for concentration dependence of diltiazem block as described above. The functional properties of these mutant Ca 2ϩ channels have been described previously (Hockerman et al., 1995) . Of the 13 amino acids in IVS6 that were mutated, only mutant channels I1460A, Y1463F, and M1464A showed decreased sensitivity to diltiazem (I1460A, IC 50 ϭ 69.5 Ϯ 7.5 M; Y1463F, IC 50 ϭ 114.4 Ϯ 19 M; M1464A, IC 50 ϭ 91.8 Ϯ 8.9 M; Fig. 3) .
Because diltiazem binds with higher affinity to L-type channels in the inactivated state, we measured the effect of Fig. 2 . Diltiazem block of wild-type ␣ 1C channels and ␣ 1C channels with single-amino-acid mutations in IIIS6. A, L-type Ba 2ϩ currents were recorded from wild-type and mutant ␣ 1C L-type channels as described under Experimental Procedures. Representative traces are shown in the absence (control) or presence of the indicated concentrations of (ϩ)-cisdiltiazem for wild-type amino acids (left), the mutant I1150A (center), and the mutant M1160A (right). B, dose-response relationships for the indicated wild type and mutant channels. In each case, the averaged, normalized current amplitudes at 5, 10, 50, 100, and 500 M diltiazem (symbols Ϯ S.E.) were plotted against the corresponding drug concentration, and the IC 50 value was determined by fitting the averaged relative current values at each diltiazem concentration to the equation, relative current ϭ 1Ϫ {1/[1ϩ(IC 50 /[diltiazem])]} (smooth lines). C, the IC 50 values of the indicated mutations in IIIS6 for diltiazem are shown Ϯ S.E. Asterisks denote that the IC 50 value for diltiazem of the indicated mutant channel is significantly different from that of wild-type ␣ 1C (Student's t test: * P Ͻ .05, ** P Ͻ .01, *** P Ͻ .001). Fig. 3 . Diltiazem block of wild-type ␣ 1C channels and ␣ 1C channels with single-amino-acid mutations in IVS6. A, L-type Ba 2ϩ currents were recorded from wild-type and mutant ␣ 1C L-type channels as described under Experimental Procedures. A, representative traces are shown in the absence (control) or presence of the indicated concentrations of (ϩ)-cis-diltiazem for wild-type (left), the mutant I1460A (center), and the mutant M1464A (right). B, dose-response relationships are shown for the indicated wild-type and mutant channels and are as described in the legend to Fig. 2 . C, the IC 50 values of the indicated mutations in IVS6 for diltiazem are shown Ϯ S.E. and were determined as described in the legend to Fig. 2 . An asterisk denotes that the IC 50 value for diltiazem of the indicated mutant channel is significantly different from that of wildtype ␣ 1C (Student's t test, * P Ͻ .05, *** P Ͻ .001).
Molecular Determinants of Ca
2؉ Channel Block by Diltiazem the single-amino-acid mutations found to decrease diltiazem sensitivity on the voltage-dependence of inactivation. In IVS6, I1460A (V 1/2 ϭ Ϫ18.2 mV), and Y1463F (V 1/2ϭ Ϫ19.2 mV), both of which significantly decreased potency of diltiazem block, were not different from wild-type ␣ 1C (V 1/2 ϭ Ϫ17.0 mV), whereas M1464A (V 1/2 ϭ Ϫ13.5 mV) was only slightly positively shifted compared with wild-type. In IIIS6, I1150A (V 1/2ϭ Ϫ13.0 mV), I1153A (V 1/2ϭ Ϫ12 mV), and V1165A (V 1/2ϭ Ϫ14.5 mV) were also slightly shifted from wild-type ␣ 1C , whereas I1156A (V 1/2ϭ Ϫ10.0 mV) and F1164A (V 1/2ϭ Ϫ9.1 mV) had greater positive shifts in voltage dependence of inactivation. Nevertheless, the holding potential used in our experiments (Ϫ60 mV) is sufficiently negative to prevent inactivation of either wild-type ␣ 1C or mutant channels, so that positive shifts in V 1/2 will not result in a smaller fraction of inactivated channels. Therefore, the reduced sensitivity of the mutant channels to diltiazem is most likely caused by changes in drug affinity and not by changes in inactivation properties. In addition to the single amino acid mutations, we also examined the effect of a triple mutation in IVS6 (YAI, Y1463IϩA1467SϩI1470A) that had previously been shown to greatly decrease block by the high-affinity phenylalkylamine (Ϫ)-D888 (Hockerman et al., 1995) . Transfer of the L-type amino acids to the corresponding positions in IVS6 of the ␣ 1A subunit has been shown to increase the sensitivity of P/Q-type Ca 2ϩ channels to diltiazem . We found that the YAI mutant is less sensitive to diltiazem than wild-type ␣ 1C (IC 50 ϭ 134.5 Ϯ 13.8 M), but only to an extent similar to the much more conservative mutation Y1463F (Fig. 3) . Furthermore, we found no appreciable increase in the IC 50 value of diltiazem for the single-amino-acid mutants A1467S and I1470A.
Discussion
Distinct but Overlapping Binding Sites for BZPs and DHPs on ␣ 1C . Using the ␣ 1A/DHPS channel, we have shown that insertion of a DHP binding site into a channel that is normally insensitive to DHP increases the sensitivity to block by diltiazem by 5-fold, making the IC 50 value of diltiazem for this mutant ␣ 1A channel virtually identical with the wild-type ␣ 1C (Fig. 1, D and F) . Because ␣ 1A/DHPS contains amino acid substitutions in three transmembrane segments, IIIS5, IIIS6, and IVS6, we assessed the contribution of amino acid residues in these three regions to diltiazem block. Mutation of both T1039 and Q1043 in IIIS5 of ␣ 1C (mutant ␣ 1C/DHPI ), removes DHP block He et al., 1997) (Fig. 1E ) and virtually eliminates DHP binding (He et al., 1997 ), but does not affect block by diltiazem (Fig.  1F) . Therefore, T1039 and Q1043 in IIIS5 are clearly involved in DHP block, but not diltiazem block, of ␣ 1C . Similarly, Y1152, F1158, F1159, and M1161 in transmembrane segment IIIS6 as well as I1470, I1471, and N1472 in segment IVS6 are required for DHP binding and block but not for BZP block (Fig. 4) . Thus, nine amino acid residues in these three transmembrane segments are involved in the DHP receptor site but not the BZP receptor site.
Other amino acid residues in transmembrane segments IIIS6 and IVS6 are required for BZP block but not for block by DHPs (Fig. 4) . I1150, F1164, and V1165 in segment IIIS6 and I1460 in segment IVS6 are important for BZP block but not for DHP binding and block. These results also support the conclusion that the BZP and DHP sites are separate.
In contrast, four amino acid residues in segments IIIS6 and IVS6 contribute to DHP binding and block and to BZP block (Fig. 4) . Y1463 and M1464 in segment IVS6 as well as I1153 and I1156 in segment IIIS6 all contribute to DHP action (Peterson et al., 1997) . These residues were included in ␣ 1A/DHPS and two other similar chimeric mutants resulting in gain of DHP binding and modulation (Hockerman et al., 1997c; Ito et al., 1997; Sinnegger et al., 1997) . These four amino acids also play an essential role in BZP block (Fig. 4) . Thus, a distinct but overlapping set of amino acid residues in IIIS6 and IVS6 comprise portions of the DHP and BZP binding sites.
The positions of the determinants of BZP block relative to those of DHP block are notable for two reasons. First, I1150 and I1460 lie more toward the extracellular ends of their respective transmembrane segments than other amino acids interacting with DHPs or PAs (Fig. 4) . This location is consistent with studies using quaternary amine BZPs indicating that BZPs approach their binding site from the extracellular side of the membrane (Hering et al., 1993) . We did, however, find that F1164 and V1165, located toward the intracellular end of IIIS6, also affect diltiazem block. Intracellular ends of S6 segments are thought to undergo conformational changes during K ϩ channel gating (Holmgren et al., 1998) . Therefore, the effects of these mutant residues may be long-distance allosteric ones secondary to effects on channel gating. Second, the aliphatic side chains of I1150, I1153, I1156, and M1160, which are required for BZP block, lie primarily on one face of the IIIS6 helix. It is possible that BZPs and DHPs bind simultaneously to different faces of the IIIS6 helix, with both drugs contacting I1153 and I1156 from opposite sides (Fig. 4) .
BZPs and DHPs interact allosterically but not competitively when binding to the ␣ 1C subunit of the L-type Ca 2ϩ channel. Diltiazem reduces both the association and dissociation rates of DHP binding, without increasing the apparent affinity for DHPs (Brauns et al., 1997) . Thus, binding of diltiazem does not prevent access of DHPs to the determinants within ␣ 1C that contribute the bulk of the binding energy. These previous studies are consistent with a model in which DHPs and diltiazem bind to distinct faces of the IIIS6 and IVS6 transmembrane segments at distinct but overlapping sites.
Similar but Nonidentical Binding Sites on ␣ 1C for Diltiazem and Phenylalkylamines. Diltiazem and PAs block L-type Ca 2ϩ channels in a similar manner. They are less potent than DHPs and, unlike DHPs, they exhibit striking frequency-dependent block (Lee and Tsien, 1983) . Previous studies have implicated transmembrane segments IIIS6 and IVS6 in block of L-type Ca 2ϩ channels by the highaffinity PA (Ϫ)-D888 (Hockerman et al., 1995 (Hockerman et al., , 1997a Doring et al., 1996; Hering et al., 1997) . Of the seven amino acid residues that may interact directly with BZPs, only I1153 in segment IIIS6 and Y1463 in segment IVS6 are also important for block by PAs (Fig. 4) . I1150, I1156, and M1160 in segment IIIS6 as well as I1460 and M1464 in segment IVS6 are required for BZP binding but not PA binding (Fig. 4) . Interestingly, F1164 and V1165, which are not implicated in DHP block, have been proposed as key determinants in the frequency dependence of both PA and BZP block Kraus et al., 1998) . Both F1164 and V1165 are conserved between ␣ 1C and ␣ 1A , and are therefore present in the ␣ 1A/DHPS mutant, where they most likely contribute substantially to diltiazem action. As noted above, it is likely that these residues are indirect allosteric effectors of state-dependent binding of PA and BZPs.
Other amino acid residues in the PA and BZP binding sites in IIIS6 and IVS6 do not overlap. Amino acids Y1152 in IIIS6 and A1467 and I1470 in IVS6 are key residues for (Ϫ)-D888 block but do not affect block by diltiazem. Indeed, ␣ 1A/DHPS has L-type sensitivity to diltiazem block despite the absence of the L-type specific residue at position 1467. Conversely, I1150, I1156, and M1160 in IIIS6 as well as I1460 and M1464 in IVS6 appear to exclusively affect diltiazem block. Our results differ from those of Hering et al. (1996) in which Y1463, A1467, and I1470 were inserted into a P/Q-type channel and increased diltiazem sensitivity. Also, M1464A had no effect on diltiazem block, but increased block by the phenylalkylamine (Ϫ)-D600 in the otherwise P/Q-type channel. It is possible that the different P/Q-type channel subtypes used in these experiments or the different expression and recording conditions in Xenopus laevis oocytes mediate the different effects on drug binding.
Amino Acid Residues Involved in Diltiazem Block of ␣ 1C Are Conservatively Substituted in ␣ 1A . A surprising finding of this study is the relatively small difference between the IC 50 values for diltiazem block of wild-type ␣ 1C and ␣ 1A . Diltiazem has been considered a relatively specific blocker of L-type Ca 2ϩ channels, although block of other channel types at higher concentrations has been noted (Diochot et al., 1995; Ishibashi et al., 1995) . Our findings suggest that the selectivity of diltiazem for L-type channels over P/Q-type channels is less than an order of magnitude. Most of the determinants of diltiazem block reported here are not conserved between ␣ 1C and ␣ 1A . How then, can the P/Q-type channel retain its relatively high degree of sensitivity to diltiazem?
A clue is provided by our results with the ␣ 1A/DHPS mutant, which contains nine L-type specific amino acids that render it highly sensitive to block by DHP (Hockerman et al., 1997c) and diltiazem. The alanine scans of IIIS6 and IVS6 identified several amino acids that are important for diltiazem block and are not included in ␣ 1A/DHPS (i.e., I1150, M1160, I1460; Fig. 4) . However, the differences between the ␣ 1A and ␣ 1C protein sequences at these positions are very conservative (i.e., V for I at 1150, F for M at 1160, and V for I at 1460; Fig.  4 ). It is likely that these hydrophobic amino acids in ␣ 1A can substitute efficiently for the nonidentical but similar hydrophobic amino acids in ␣ 1C , and that the importance of these positions in diltiazem block comes to light only when the more drastic substitution of alanine is made. We have previously emphasized the importance of systematic mutagenesis for identifying functional properties of amino acids conserved between channel subtypes (Hockerman et al., 1995 (Hockerman et al., , 1997a Peterson et al., 1996; Peterson et al., 1997) . This result emphasizes the utility of systematic alanine substitutions in locating binding determinants where subtype differences are conservative enough to support the same function. Further analysis of amino acid differences between the ␣ 1A and ␣ 1C in positions that we found to be important for diltiazem block reveals that three of the remaining four nonconserved residues are relatively conservative aliphatic-to-hydrophobic aromatic substitutions (i.e., I1153 to F, I1156 to F, M1464 to F). One nonconserved position, Y1463, is replaced by isoleucine in ␣ 1A , a substantial difference in side chain character. In fact, the removal of the tyrosine hydroxyl in the Y1463F mutation has nearly the same effect as substitution to alanine in the context of the YAI mutation (Fig. 3) . Thus, at the positions critical for diltiazem block, only one amino acid is substantially different between ␣ 1A and ␣ 1C whereas several positions contain conservative amino acid substitutions. These conservative substitutions along with conserved residues F1164 and V1165 allow relatively potent block of ␣ 1A by diltiazem.
